Drug Information

Drug General Information
Drug ID
D05PZB
Former ID
DCL000059
Drug Name
AT9283
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [533017], [542864]
Therapeutic Class
Anticancer Agents
Company
Astex Therape.
Formula
C19H23N7O2
InChI
InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13,20,25H,2-3,5-8,11H2,(H2,21,24,27)/b18-17-
InChIKey
VRXXZJLHPWWXIX-ZCXUNETKSA-N
PubChem Compound ID
11696609
PubChem Substance ID
16801122, 42863522, 77625336, 99436915, 104120111, 124757023, 125163827, 131480765, 134338763, 136367324, 136368082, 136920272, 137110293, 144115642, 162011406, 162037457, 163398977, 163844918, 164045558, 164193993, 172918160, 177748912, 180191808, 186014825, 188899588, 239968902, 249565632
Target and Pathway
Target(s) Aurora kinase B Target Info Modulator [533017]
Aurora kinase A Target Info Modulator [533017]
KEGG Pathway Oocyte meiosis
Pathway Interaction Database Aurora B signaling
Signaling by Aurora kinases
Aurora C signaling
FOXM1 transcription factor network
Aurora A signalingaurora_b_pathway:Aurora B signaling
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signaling
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M Transition
WikiPathways Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Regulation of Microtubule Cytoskeleton
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteins
References
Ref 533017A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
Ref 542864(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7949).
Ref 533017A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.